Ultragenyx Pharmaceutical’s (RARE) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a research report released on Tuesday,Benzinga reports. They currently have a $80.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on RARE. Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a “neutral” rating on the stock in a research report on Monday, July 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $105.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, September 5th. Wells Fargo & Company dropped their price objective on Ultragenyx Pharmaceutical from $88.00 to $65.00 and set an “overweight” rating on the stock in a research report on Thursday, July 10th. Guggenheim reaffirmed a “buy” rating and set a $64.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, June 20th. Finally, William Blair initiated coverage on Ultragenyx Pharmaceutical in a research report on Wednesday, May 28th. They set an “outperform” rating and a $65.00 price objective on the stock. Eleven research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $81.50.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $31.23 on Tuesday. The business has a 50-day moving average price of $29.88 and a 200 day moving average price of $34.53. The company has a market capitalization of $3.01 billion, a P/E ratio of -5.65 and a beta of 0.21. Ultragenyx Pharmaceutical has a 1-year low of $25.81 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million during the quarter, compared to the consensus estimate of $161.37 million. Ultragenyx Pharmaceutical had a negative return on equity of 237.48% and a negative net margin of 87.34%.The firm’s quarterly revenue was up 13.2% on a year-over-year basis. During the same period in the previous year, the company posted ($1.52) earnings per share. Ultragenyx Pharmaceutical has set its FY 2025 guidance at EPS. On average, analysts anticipate that Ultragenyx Pharmaceutical will post -5.18 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Ultragenyx Pharmaceutical news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of Ultragenyx Pharmaceutical stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $37.39, for a total transaction of $89,922.95. Following the completion of the sale, the director owned 15,344 shares of the company’s stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Knott David M Jr acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $1,738,000. Cubist Systematic Strategies LLC acquired a new stake in Ultragenyx Pharmaceutical during the 1st quarter worth about $4,400,000. Squarepoint Ops LLC acquired a new stake in Ultragenyx Pharmaceutical during the 4th quarter worth about $3,702,000. Ameriprise Financial Inc. grew its position in Ultragenyx Pharmaceutical by 8.4% during the 4th quarter. Ameriprise Financial Inc. now owns 13,396 shares of the biopharmaceutical company’s stock worth $564,000 after purchasing an additional 1,039 shares during the period. Finally, Vestal Point Capital LP grew its position in Ultragenyx Pharmaceutical by 100.0% during the 4th quarter. Vestal Point Capital LP now owns 1,500,000 shares of the biopharmaceutical company’s stock worth $63,105,000 after purchasing an additional 750,000 shares during the period. Institutional investors and hedge funds own 97.67% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.